A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures
Authors' conclusion
This longitudinal study of 180 patients with RA commencing etanercept has identified several putative protein biomarkers of treatment response to this drug, one of which was replicated in an independent cohort.
Study context
- Population
- Patients with RA starting the bDMARD etanercept, UK-based prospective multicentre study
- Participants
- 180 vs 58
- Exposure
- Discovery vs Validation
- Discoveryn = 180
- Validationn = 58
- Outcome
- Pretreatment serum proteins associated with RA clinical outcome measures:
- DAS28
- Its subcomponents
- DAS28 <2.6 remission
- Follow-up
- 3 months
Methodological detailsmulticentre, proteomic (SWATH-MS), discovery and independent replication datasets
- Multicentre
- Proteomic (SWATH-MS)
- Discovery and independent replication datasets
Main finding
As reported in the abstract
Proteins associated with RA clinical outcome measures
- Proteins significantly associated with RA clinical outcome measures
- 10
Observational data: associations, not effects.
Further findings
Subnetwork analysis of the 10 proteins
- Strongest associations with acute phase and acute inflammatory responses
Original publication
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures. Rheumatology (Oxford). Published 30 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →